Fecal microbiota transplantation: past, present and future

  title={Fecal microbiota transplantation: past, present and future},
  author={Olga C. Aroniadis and Lawrence J Brandt},
  journal={Current Opinion in Gastroenterology},
Purpose of reviewFecal microbiota transplantation (FMT) re-establishes a balanced intestinal flora with resultant cure of recurrent Clostridium difficile infection (RCDI). FMT has also been used to treat other gastrointestinal (GI) diseases including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation and a variety of non-GI disorders. The purpose of this review is to discuss the intestinal microbiota and FMT treatment of GI and non-GI diseases. Recent… 

Faecal microbiota transplantation: applications and limitations in treating gastrointestinal disorders

Results from clinical studies are conflicting, which reflects the gap in knowledge of the microbiome composition and function, and highlights the need for a more defined and personalised microbial isolation and transfer.

Fecal microbiota transplantation broadening its application beyond intestinal disorders.

This review shows that it is an exciting time in the burgeoning science of FMT application in previously unexpected areas, including metabolic diseases, neuropsychiatric disorders, autoimmune diseases, allergic disorders, and tumors.

Recent Update in Fecal Microbiota Transplantation

Gut microbiota can be a next generation's biotherapy for promotion of health and treatment of chronic diseases and medicines and diagnostic tools that are under development are summarized.

Modulating the microbiota in inflammatory bowel diseases: prebiotics, probiotics or faecal transplantation?

FMT has been successfully applied to treat patients with even recalcitrant Clostridium difficile infection and the majority of studies suggest that FMT may be an effective treatment option although the evidence is still limited.

Fecal microbiota transplantation in gastrointestinal and extraintestinal disorders.

The aim of this review is to paint the landscape of current evidence of FMT in different fields of application (including irritable bowel syndrome, inflammatory bowel disease, liver disorders, decolonization of multidrug-resistant bacteria, metabolic disorders and neurological disorders), as well as to discuss the current regulatory scenario of F MT, and hypothesize future directions.

Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?

Promising therapeutic value in extraintestinal diseases associated with gut microbial dysbiosis are discussed, including liver, metabolic, chronic kidney, neuropsychiatric, allergic, autoimmune, and hematological diseases as well as tumors.

The potential role of fecal microbiota transplantation in the treatment of inflammatory Bowel disease

A method for the administration of fecal matters from a healthy donor to the inflamed colon called fecal microbiota transplantation (FMT) aiming to correct the underlying dysbiosis in the gut as one of the major driving force for the inflammatory process.

Fecal Microbiota Transplantation: A New Old Kid on the Block for the Management of Gut Microbiota-related Disease

Cutting-edge technologies for the assessment of gut microbiota composition and the development of well-designed, large randomized trials are needed to put such perspectives into practice and improve the therapeutic potential of FMT.

Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome.

In this review, it will be discussed how exogenous factors, e.g. antibiotics, can cause disbalance in the intestinal microbiota and thereby contribute to the development of IBS.

Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options

The bacterial profile shows that dominant and minor phyla are present in the gastrointestinal tract, and from the proximal to the distal segments of the gut the bacterial density gradually increases, reaching an estimated 1011 to 1012 bacteria per gram of colonic content.



Fecal microbiota transplantation and emerging applications

The field of microbiota-related disorders is currently in its infancy; it certainly is an exciting time in the burgeoning science of FMT and the authors expect to see new and previously unexpected applications in the near future.

Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.

  • E. GoughHenna ShaikhA. Manges
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2011
Effectiveness varied by route of instillation, relationship to stool donor, volume of IMT given, and treatment before infusion, but findings can guide physicians interested in implementing the procedure until better designed studies are conducted to confirm best practices.

Fecal microbiota transplantation for recurrent clostridium difficile infection.

With a better understanding of the intricacies of the colonic microbiome and its role in colonic pathophysiology, FMT has the potential to become the standard of care for CDI treatment, and a potential answer to other intestinal disorders in years to come.

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

Patient stratification by GI microbiota provides further evidence that CD represents a spectrum of disease states and suggests that treatment of some forms of IBD may be facilitated by redress of the detected microbiological imbalances.

Using Probiotics in Gastrointestinal Disorders

Although sufficient evidence is not currently available to provide a clear guidance on the best probiotic for a particular clinical indication, key scientific concepts are now emerging and will provide practical information on the use of these products in clinical practice.

Treatment of Ulcerative Colitis Using Fecal Bacteriotherapy

Colonic infusion of donor human intestinal flora can reverse UC in selected patients and anecdotal results support the concept of abnormal bowel flora or even a specific, albeit unidentified, bacterial pathogen causing UC.

Changes in the Composition of the Human Fecal Microbiome After Bacteriotherapy for Recurrent Clostridium difficile-associated Diarrhea

The striking similarity of the recipient's and donor's intestinal microbiota following after bacteriotherapy suggests that the donor's bacteria quickly occupied their requisite niches resulting in restoration of both the structure and function of the microbial communities present.

Gut microbiota in health and disease.

The advances in modeling and analysis of gut microbiota will further the authors' knowledge of their role in health and disease, allowing customization of existing and future therapeutic and prophylactic modalities.

Bacteriotherapy Using Fecal Flora: Toying With Human Motions

Fecal bacteriotherapy uses the complete normal human flora as a therapeutic probiotic mixture of living organisms in patients with inflammatory bowel disease, irritable bowel syndrome, and chronic constipation, and possible mechanisms of action and potential applications explored.